Literature DB >> 30542115

NTRK1 is a positive regulator of YAP oncogenic function.

Xinyuan Yang1,2, He Shen2, Brian Buckley3, Yanmin Chen2, Nuo Yang4, Ashley L Mussell2, Mikhail Chernov3, Lester Kobzik5, Costa Frangou5, Su-Xia Han6, Jianmin Zhang7.   

Abstract

Multiple cancer signalling networks take part in regulatory crosstalks with the Hippo tumour suppressor pathway through the transcriptional cofactor Yes-associated protein (YAP). Nevertheless, how YAP is controlled by pathway crosstalks in tumourigenesis remains poorly understood. Here, we performed a targeted kinase inhibitor screen in human cancer cells to identify novel Hippo pathway regulators. Notably, we identified the nerve growth factor (NGF) receptor tyrosine kinase (NTRK1), a molecule not previously associated with Hippo signalling. NTRK1 inhibition decreased YAP-driven transcription, cancer cell proliferation and migration. Furthermore, using a complementary functional genomics approach and mouse xenograft models, we show that NTRK1 regulates YAP oncogenic activity in vivo. Mechanistically, NTRK1 inhibition was found to induce large suppressor kinase 1 (LATS1) phosphorylation and to control YAP subcellular localization. Taken together, these results provide compelling evidence of crosstalks between the NGF-NTRK1 and Hippo cancer pathways.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30542115      PMCID: PMC6686201          DOI: 10.1038/s41388-018-0609-1

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  30 in total

Review 1.  Origin and evolution of the Trk family of neurotrophic receptors.

Authors:  Elia Benito-Gutiérrez; Jordi Garcia-Fernàndez; Joan X Comella
Journal:  Mol Cell Neurosci       Date:  2005-10-25       Impact factor: 4.314

2.  MARK4 inhibits Hippo signaling to promote proliferation and migration of breast cancer cells.

Authors:  Emad Heidary Arash; Ahmed Shiban; Siyuan Song; Liliana Attisano
Journal:  EMBO Rep       Date:  2017-02-09       Impact factor: 8.807

3.  Transforming properties of YAP, a candidate oncogene on the chromosome 11q22 amplicon.

Authors:  Michael Overholtzer; Jianmin Zhang; Gromoslaw A Smolen; Beth Muir; Wenmei Li; Dennis C Sgroi; Chu-Xia Deng; Joan S Brugge; Daniel A Haber
Journal:  Proc Natl Acad Sci U S A       Date:  2006-08-07       Impact factor: 11.205

4.  PTPN14 forms a complex with Kibra and LATS1 proteins and negatively regulates the YAP oncogenic function.

Authors:  Kayla E Wilson; Ying-Wei Li; Nuo Yang; He Shen; Ashley R Orillion; Jianmin Zhang
Journal:  J Biol Chem       Date:  2014-07-14       Impact factor: 5.157

Review 5.  The two faces of Hippo: targeting the Hippo pathway for regenerative medicine and cancer treatment.

Authors:  Randy Johnson; Georg Halder
Journal:  Nat Rev Drug Discov       Date:  2013-12-13       Impact factor: 84.694

6.  Molecular Features of the YAP Inhibitor Verteporfin: Synthesis of Hexasubstituted Dipyrrins as Potential Inhibitors of YAP/TAZ, the Downstream Effectors of the Hippo Pathway.

Authors:  Floriane Gibault; Fabrice Bailly; Matthieu Corvaisier; Mathilde Coevoet; Guillemette Huet; Patricia Melnyk; Philippe Cotelle
Journal:  ChemMedChem       Date:  2017-04-20       Impact factor: 3.466

Review 7.  The Salvador-Warts-Hippo pathway - an emerging tumour-suppressor network.

Authors:  Kieran Harvey; Nicolas Tapon
Journal:  Nat Rev Cancer       Date:  2007-03       Impact factor: 60.716

8.  A genetic screen identifies an LKB1-MARK signalling axis controlling the Hippo-YAP pathway.

Authors:  Morvarid Mohseni; Jianlong Sun; Allison Lau; Stephen Curtis; Jeffrey Goldsmith; Victor L Fox; Chongjuan Wei; Marsha Frazier; Owen Samson; Kwok-Kin Wong; Kwok-Kim Wong; Carla Kim; Fernando D Camargo
Journal:  Nat Cell Biol       Date:  2013-12-22       Impact factor: 28.824

Review 9.  Nerve growth factor: role in growth, differentiation and controlling cancer cell development.

Authors:  Luigi Aloe; Maria Luisa Rocco; Bijorn Omar Balzamino; Alessandra Micera
Journal:  J Exp Clin Cancer Res       Date:  2016-07-21

Review 10.  Inhibiting TRK Proteins in Clinical Cancer Therapy.

Authors:  Allison M Lange; Hui-Wen Lo
Journal:  Cancers (Basel)       Date:  2018-04-04       Impact factor: 6.639

View more
  7 in total

Review 1.  Hippo Signaling Pathway as a Central Mediator of Receptors Tyrosine Kinases (RTKs) in Tumorigenesis.

Authors:  Taha Azad; Reza Rezaei; Abera Surendran; Ragunath Singaravelu; Stephen Boulton; Jaahnavi Dave; John C Bell; Carolina S Ilkow
Journal:  Cancers (Basel)       Date:  2020-07-24       Impact factor: 6.639

2.  ALKBH5 suppresses tumor progression via an m6A-dependent epigenetic silencing of pre-miR-181b-1/YAP signaling axis in osteosarcoma.

Authors:  Ye Yuan; Gege Yan; Mingyu He; Hong Lei; Linqiang Li; Yang Wang; Xiaoqi He; Guanghui Li; Quan Wang; Yuelin Gao; Zhezhe Qu; Zhongting Mei; Zhihua Shen; Jiaying Pu; Ao Wang; Wei Zhao; Huiwei Jiang; Weijie Du; Lei Yang
Journal:  Cell Death Dis       Date:  2021-01-11       Impact factor: 8.469

3.  Genome-wide analysis identifies critical DNA methylations within NTRKs genes in colorectal cancer.

Authors:  Zijian Chen; Zenghong Huang; Yanxin Luo; Qi Zou; Liangliang Bai; Guannan Tang; Xiaolin Wang; Guangwen Cao; Meijin Huang; Jun Xiang; Huichuan Yu
Journal:  J Transl Med       Date:  2021-02-16       Impact factor: 5.531

Review 4.  Alternative Energy: Breaking Down the Diverse Metabolic Features of Lung Cancers.

Authors:  Kasey R Cargill; William L Hasken; Carl M Gay; Lauren A Byers
Journal:  Front Oncol       Date:  2021-10-21       Impact factor: 6.244

Review 5.  Emerging Importance of Tyrosine Kinase Inhibitors against Cancer: Quo Vadis to Cure?

Authors:  Raj Kumar Mongre; Chandra Bhushan Mishra; Arvind Kumar Shukla; Amresh Prakash; Samil Jung; Md Ashraf-Uz-Zaman; Myeong-Sok Lee
Journal:  Int J Mol Sci       Date:  2021-10-28       Impact factor: 5.923

6.  Computing microRNA-gene interaction networks in pan-cancer using miRDriver.

Authors:  Banabithi Bose; Matthew Moravec; Serdar Bozdag
Journal:  Sci Rep       Date:  2022-03-08       Impact factor: 4.379

Review 7.  Coregulation of pathways in lung cancer patients with EGFR mutation: therapeutic opportunities.

Authors:  Rafael Rosell; Andrés Felipe Cardona; Oscar Arrieta; Andrés Aguilar; Masaoki Ito; Carlos Pedraz; Jordi Codony-Servat; Mariacarmela Santarpia
Journal:  Br J Cancer       Date:  2021-08-09       Impact factor: 7.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.